Not available
Quote | Iovance Biotherapeutics Inc. (NASDAQ:IOVA)
Last: | $12.50 |
---|---|
Change Percent: | 0.25% |
Open: | $11.75 |
Close: | $12.50 |
High: | $12.9974 |
Low: | $11.75 |
Volume: | 5,755,641 |
Last Trade Date Time: | 05/01/2024 03:00:00 am |
News | Iovance Biotherapeutics Inc. (NASDAQ:IOVA)
SAN CARLOS, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2024 ...
2024-04-28 14:44:00 ET There's a lot of excitement around Iovance Biotherapeutics (NASDAQ: IOVA) as its shares are up over 40% year-to-date. Investors and analysts both see even more upside for this mid-cap biotech stock in the long run. Today, however, the company remains deepl...
Message Board Posts | Iovance Biotherapeutics Inc. (NASDAQ:IOVA)
Subject | By | Source | When |
---|---|---|---|
Citing feedback, the company announced that the design | jondoeuk | investorshub | 07/10/2023 5:02:29 PM |
$IOVA Price gaining | Watts Watt | investorshub | 07/10/2023 5:37:07 AM |
Do we have a winner?Turn around time? | jondoeuk | investorshub | 07/08/2023 7:59:28 AM |
$IOVA Lets go go go go... Up up and away we go. | Watts Watt | investorshub | 07/05/2023 10:58:06 PM |
$IOVA bulls and bears | jondoeuk | investorshub | 07/05/2023 5:31:05 PM |
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
SAN CARLOS, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2024 ...
2024-04-28 14:44:00 ET There's a lot of excitement around Iovance Biotherapeutics (NASDAQ: IOVA) as its shares are up over 40% year-to-date. Investors and analysts both see even more upside for this mid-cap biotech stock in the long run. Today, however, the company remains deepl...
SAN CARLOS, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biote...